Cover Image
Market Research Report

Middle East and Africa Drug Delivery Market - Industry Trends and Forecast to 2027

Published by Data Bridge Market Research Private Limited Product code 932720
Published Content info 100 Pages
Delivery time: 1-2 business days
Price
Back to Top
Middle East and Africa Drug Delivery Market - Industry Trends and Forecast to 2027
Published: March 1, 2020 Content info: 100 Pages
Description

Middle East and Africa drug delivery market is projected to register a substantial growth in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation

Middle East and Africa Drug Delivery Market, By Product Type (Oral Drug Delivery, Pulmonary Drug Delivery, Injectable Drug Delivery, Opthalmic Drug Delivery, Nasal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, Transmucosal Drug Delivery), End User (Hospitals, Community Healthcare, Home Healthcare, Clinics, Others), Distribution Channel (Hospital Pharmacies, Pharmacy Stores, Direct Tenders, Online Pharmacy), Country (South Africa, Rest of Middle East & Africa), Market Trends and Forecast to 2027.

Some of the major factors contributing to the growth of the Middle East and Africa drug delivery market are:

  • Rising prevalence of chronic disease and non-chronic disease
  • Technological development

Market Players

The Key Market Players for Middle East and Africa drug delivery market are listed below:

  • Johnson & Johnson services, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Pfizer Inc.
  • 3M
  • GlaxoSmithKline Plc
  • Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.)
  • Nemera
  • Sanofi
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 PRODUCTS LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 SECONDARY SOURCES
  • 2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

  • 5.1 DRIVERS
    • 5.1.1 RISING PREVALENCE OF CHRONIC DISEASE AND NON CHRONIC DISEASE
    • 5.1.2 GROWTH IN THE DEVELOPMENT OF BIOLOGICS
    • 5.1.3 TECHNOLOGICAL DEVELOPMENT
    • 5.1.4 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT
    • 5.1.5 RISING ACCEPTANCE OF SELF ADMINISTERING DRUGS
  • 5.2 RESTRAINTS
    • 5.2.1 RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS
    • 5.2.2 HIGH COSTS OF DRUGS
    • 5.2.3 STRINGENT REGULATORY SCENARIO
    • 5.2.4 PRODUCT RECALLS

  • 5.3 OPPORTUNITIES
    • 5.3.1 RISING DEMAND FOR BIOSIMILARS AND GENERIC DRUGS
    • 5.3.2 THERAPEUTIC ADVANCEMENTS
    • 5.3.3 TREND OF MERGER AND ACQUISITIONS AND COLLABORATIONS
    • 5.3.4 FOCUS ON PATIENTS' NEEDS
    • 5.3.5 DEVELOPING AND NEW EMERGING REVENUE POCKETS
  • 5.4 CHALLENGES
    • 5.4.1 SIDE EFFECTS OF DRUG DELIVERY SYSTEMS
    • 5.4.2 PATENT EXPIRY AND PATENT CLIFF
    • 5.4.3 ALTERNATIVES TO DRUG DELIVERY

6 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET, BY PRODUCT TYPE

  • 6.1 OVERVIEW
  • 6.2 ORAL DRUG DELIVERY
    • 6.2.1 BY FORM
      • 6.2.1.1 SOLID ORAL DRUGS
        • 6.2.1.1.1 TABLETS
        • 6.2.1.1.2 CAPSULES
        • 6.2.1.1.3 PILLS
        • 6.2.1.1.4 POWDERS
      • 6.2.1.2 LIQUID ORAL DRUGS
        • 6.2.1.2.1 SYRUPS
        • 6.2.1.2.2 SOLUTIONS
      • 6.2.1.3 semi solid oral drugs
        • 6.2.1.3.1 GELS
        • 6.2.1.3.2 EMULSIONS
        • 6.2.1.3.3 ELIXIRS
  • 6.3 INJECTABLE DRUG DELIVERY
    • 6.3.1 INJECTABLE DRUG DELIVERY DEVICES
      • 6.3.1.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES
        • 6.3.1.1.1 BY MATERIAL TYPE
        • 6.3.1.1.1.1 GLASS
        • 6.3.1.1.1.2 PLASTIC
        • 6.3.1.1.2 BY PRODUCT TYPE
        • 6.3.1.1.2.1 FILLABLE
        • 6.3.1.1.2.2 PRE-FILLED
        • 6.3.1.1.3 BY USABILITY
        • 6.3.1.1.3.1 REUSABLE SYRINGES
        • 6.3.1.1.3.2 DISPOSABLE SYRINGES

      • 6.3.1.2 SELF-INJECTION DRUG DELIVERY
        • 6.3.1.2.1 NEEDLE FREE INJECTORS
        • 6.3.1.2.2 WEARABLE INJECTORS
        • 6.3.1.2.3 PEN INJECTOR
        • 6.3.1.2.4 AUTO INJECTORS
        • 6.3.1.2.5 OTHERS
    • 6.3.2 INJECTABLE DRUG DELIVERY FORMULATIONS
      • 6.3.2.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
      • 6.3.2.2 NOVEL DRUG DELIVERY FORMULATIONS
      • 6.3.2.3 LONG ACTING INJECTION FORMULATIONS
  • 6.4 OPHTHALMIC DRUG DELIVERY
      • 6.4.1.1 OCULAR DRUG DELIVERY FORMULATIONS
        • 6.4.1.1.1 LIQUID OCULAR DRUG DELIVERY FORMULATIONS
        • 6.4.1.1.1.1 SOLUTIONS
        • 6.4.1.1.1.2 SUSPENSIONS
        • 6.4.1.1.2 SEMI SOLID OCULAR DRUG DELIVERY FORMULATIONS
        • 6.4.1.1.2.1 GELS
        • 6.4.1.1.2.2 OINTMENTS
      • 6.4.1.2 OCULAR DRUG DELIVERY DEVICES
        • 6.4.1.2.1.1 DRUG COATED CONTACT LENSES
        • 6.4.1.2.1.2 OCULAR INSERTS
  • 6.5 NASAL DRUG DELIVERY
    • 6.5.1 NASAL DROPS
    • 6.5.2 NASAL SPRAYS
    • 6.5.3 NASAL POWDERS
    • 6.5.4 NASAL GELS
  • 6.6 TOPICAL DRUG DELIVERY
    • 6.6.1 TRANSDERMAL DRUG DELIVERY DEVICES
      • 6.6.1.1 TRANSDERMAL PATCHES
      • 6.6.1.2 TRANSDERMAL GELS
    • 6.6.2 TRANSDERMAL DRUG DELIVERY FORMULATIONS
      • 6.6.2.1 LIQUID TOPICAL DRUG DELIVERY FORMULATIONS
        • 6.6.2.1.1 SUSPENSIONS
        • 6.6.2.1.2 SOLUTIONS
      • 6.6.2.2 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS
        • 6.6.2.2.1 OINTMENTS
        • 6.6.2.2.2 CREAMS
        • 6.6.2.2.3 LOTIONS
        • 6.6.2.2.4 GELS
        • 6.6.2.2.5 PASTES
      • 6.6.2.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS
        • 6.6.2.3.1 POWDER
        • 6.6.2.3.2 SUPPOSITORS
  • 6.7 IMPLANTABLE DRUG DELIVERY
    • 6.7.1 PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
    • 6.7.2 ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
  • 6.8 TRANSMUCOSAL DRUG DELIVERY
    • 6.8.1 ORAL TRANSMUCOSAL DRUG DELIVERY
      • 6.8.1.1 BUCCAL DRUG DELIVERY
      • 6.8.1.2 SUBLINGUAL DRUG DELIVERY
    • 6.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY
      • 6.8.2.1 RECTAL TRANSMUCOSAL DRUG DELIVERY
      • 6.8.2.2 VAGINAL TRANSMUCOSAL DRUG DELIVERY
  • 6.9 PULMONARY DRUG DELIVERY
    • 6.9.1 METERED DOSE INHALERS (MDI)
    • 6.9.2 DRY POWDER INHALERS (DPI)
    • 6.9.3 NEBULIZERS
      • 6.9.3.1 JET NEBULIZERS
      • 6.9.3.2 ULTRASONIC NEBULIZERS
      • 6.9.3.3 SOFT MIST NEBULIZERS

7 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET, BY END USER

  • 7.1 OVERVIEW
  • 7.2 HOSPITALS
  • 7.3 HOME HEALTHCARE
  • 7.4 CLINICS
  • 7.5 COMMUNITY HEALTHCARE
  • 7.6 OTHERS

8 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

  • 8.1 OVERVIEW
  • 8.2 DIRECT TENDERS
  • 8.3 HOSPITAL PHARMACIES
  • 8.4 PHARMACY STORES
  • 8.5 ONLINE PHARMACY

9 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET, BY GEOGRAPHY

  • 9.1 MIDDLE EAST AND AFRICA
    • 9.1.1 SOUTH AFRICA
    • 9.1.2 REST OF MIDDLE EAST AND AFRICA
    • 9.1.3 EGYPT
    • 9.1.4 SAUDI ARABIA
    • 9.1.5 UNITED ARAB EMIRATES
    • 9.1.6 ISRAEL

10 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET, COMPANY LANDSCAPE

  • 10.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

11 COMPANY PROFILES

  • 11.1 JOHNSON & JOHNSON SERVICES, INC.
    • 11.1.1 COMPANY SNAPSHOT
    • 11.1.2 REVENUE ANALYSIS
    • 11.1.3 COMPANY SHARE ANALYSIS
    • 11.1.4 PRODUCT PORTFOLIO
    • 11.1.5 RECENT DEVELOPMENTS
  • 11.2 NOVARTIS AG
    • 11.2.1 COMPANY SNAPSHOT
    • 11.2.2 REVENUE ANALYSIS
    • 11.2.3 COMPANY SHARE ANALYSIS
    • 11.2.4 PRODUCT PORTFOLIO
    • 11.2.5 RECENT DEVELOPMENTS
  • 11.3 F. HOFFMANN-LA ROCHE LTD
    • 11.3.1 COMPANY SNAPSHOT
    • 11.3.2 REVENUE ANALYSIS
    • 11.3.3 COMPANY SHARE ANALYSIS
    • 11.3.4 PRODUCT PORTFOLIO
    • 11.3.5 RECENT DEVELOPMENTS
  • 11.4 BAYER AG
    • 11.4.1 COMPANY SNAPSHOT
    • 11.4.2 REVENUE ANALYSIS
    • 11.4.3 COMPANY SHARE ANALYSIS
    • 11.4.4 PRODUCT PORTFOLIO
    • 11.4.5 RECENT DEVELOPMENTS

  • 11.5 PFIZER INC.
    • 11.5.1 COMPANY SNAPSHOT
    • 11.5.2 REVENUE ANALYSIS
    • 11.5.3 COMPANY SHARE ANALYSIS
    • 11.5.4 BRAND PORTFOLIO
    • 11.5.5 RECENT DEVELOPMENTS
  • 11.6 3M
    • 11.6.1 COMPANY SNAPSHOT
    • 11.6.2 REVENUE ANALYSIS
    • 11.6.3 PRODUCT PORTFOLIO
    • 11.6.4 RECENT DEVELOPMENTS
  • 11.7 ANTARES PHARMA
    • 11.7.1 COMPANY SNAPSHOT
    • 11.7.2 REVENUE ANALYSIS
    • 11.7.3 PRODUCT PORTFOLIO
    • 11.7.4 RECENT DEVELOPMENTS
  • 11.8 GLAXOSMITHKLINE PLC
    • 11.8.1 COMPANY SNAPSHOT
    • 11.8.2 REVENUE ANALYSIS
    • 11.8.3 PRODUCT PORTFOLIO
    • 11.8.4 RECENT DEVELOPMENTS
  • 11.9 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
    • 11.9.1 COMPANY SNAPSHOT
    • 11.9.2 REVENUE ANALYSIS
    • 11.9.3 PRODUCT PORTFOLIO
    • 11.9.4 RECENT DEVELOPMENTS
  • 11.10 NEMERA
    • 11.10.1 COMPANY SNAPSHOT
    • 11.10.2 PRODUCT PORTFOLIO
    • 11.10.3 RECENT DEVELOPMENTS
  • 11.11 SANOFI
    • 11.11.1 COMPANY SNAPSHOT
    • 11.11.2 REVENUE ANALYSIS
    • 11.11.3 PRODUCT PORTFOLIO
    • 11.11.4 RECENT DEVELOPMENTS

12 QUESTIONNAIRE

13 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 LIST OF FDA APPROVED BIOLOGICS, IN 2016
  • TABLE 2 MOST EXPENSIVE DRUGS IN THE U.S.
  • TABLE 3 MAJOR PRODUCT RECALLS IN THE DRUG DELIVERY MARKET, 2019-2020
  • TABLE 4 LIST OF FDA APPROVED GENERICS, IN 2019
  • TABLE 5 PATENT EXPIRY OF DRUGS, 2019
  • TABLE 6 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET, BY PRODUCT TYPE , 2018-2027 (USD BILLION)
  • TABLE 7 MIDDLE EAST AND AFRICA ORAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 8 MIDDLE EAST AND AFRICA ORAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 9 MIDDLE EAST AND AFRICA SOLID ORAL DRUG IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 10 MIDDLE EAST AND AFRICA LIQUID ORAL DRUG IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 11 MIDDLE EAST AND AFRICA SEMI SOLID ORAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 12 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 13 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 14 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 15 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY MATERIAL, 2018-2027 (USD BILLION)
  • TABLE 16 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE 2018-2027 (USD BILLION)
  • TABLE 17 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 18 MIDDLE EAST AND AFRICA SELF-INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 19 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 20 MIDDLE EAST AND AFRICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 21 MIDDLE EAST AND AFRICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 22 MIDDLE EAST AND AFRICA OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 23 MIDDLE EAST AND AFRICA LIQUID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 24 MIDDLE EAST AND AFRICA SEMI SOLID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 25 MIDDLE EAST AND AFRICA OCULAR DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 26 MIDDLE EAST AND AFRICA NASAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 27 MIDDLE EAST AND AFRICA NASAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 28 MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 29 MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 30 MIDDLE EAST AND AFRICA TRANSDERMAL DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 31 MIDDLE EAST AND AFRICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 32 MIDDLE EAST AND AFRICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 33 MIDDLE EAST AND AFRICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 34 MIDDLE EAST AND AFRICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 35 MIDDLE EAST AND AFRICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 36 MIDDLE EAST AND AFRICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 37 MIDDLE EAST AND AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 38 MIDDLE EAST AND AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 39 MIDDLE EAST AND AFRICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 40 MIDDLE EAST AND AFRICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 41 MIDDLE EAST AND AFRICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 42 MIDDLE EAST AND AFRICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 43 MIDDLE EAST AND AFRICA NEBULIZERS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 44 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET, BY END USER, 2018-2027 (USD BILLION)
  • TABLE 45 MIDDLE EAST AND AFRICA HOPITALS IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 46 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 47 MIDDLE EAST AND AFRICA CLINICS IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 48 MIDDLE EAST AND AFRICA COMMUNITY HEALTHCARE IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 49 MIDDLE EAST AND AFRICA OTHERS IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 50 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
  • TABLE 51 MIDDLE EAST AND AFRICA DIRECT TENDERS IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 52 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 53 MIDDLE EAST AND AFRICA PHARMACY STORES IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 54 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 55 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET, BY COUNTRY, 2018-2027 (USD BILLION)
  • TABLE 56 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 57 MIDDLE EAST AND AFRICA ORAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 58 MIDDLE EAST AND AFRICA SOLID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 59 MIDDLE EAST AND AFRICA LIQUID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 60 MIDDLE EAST AND AFRICA SEMI-SOLID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 61 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 62 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 63 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY MATERIAL, 2018-2027 (USD BILLION)
  • TABLE 64 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE 2018-2027 (USD BILLION)
  • TABLE 65 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 66 MIDDLE EAST AND AFRICA SELF-INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 67 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 68 MIDDLE EAST AND AFRICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 69 MIDDLE EAST AND AFRICA OCULAR DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 70 MIDDLE EAST AND AFRICA OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 71 MIDDLE EAST AND AFRICA LIQUID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 72 MIDDLE EAST AND AFRICA SEMI-SOLID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 73 MIDDLE EAST AND AFRICA NASAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 74 MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 75 MIDDLE EAST AND AFRICA TRANSDERMAL DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 76 MIDDLE EAST AND AFRICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 77 MIDDLE EAST AND AFRICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 78 MIDDLE EAST AND AFRICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 79 MIDDLE EAST AND AFRICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 80 MIDDLE EAST AND AFRICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 81 MIDDLE EAST AND AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 82 MIDDLE EAST AND AFRICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 83 MIDDLE EAST AND AFRICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 84 MIDDLE EAST AND AFRICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 85 MIDDLE EAST AND AFRICA NEBULIZERS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 86 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET, BY END USER, 2018-2027 (USD BILLION)
  • TABLE 87 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
  • TABLE 88 SOUTH AFRICA DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 89 SOUTH AFRICA ORAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 90 SOUTH AFRICA SOLID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 91 SOUTH AFRICA LIQUID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 92 SOUTH AFRICA SEMI-SOLID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 93 SOUTH AFRICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 94 SOUTH AFRICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 95 SOUTH AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY MATERIAL, 2018-2027 (USD BILLION)
  • TABLE 96 SOUTH AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE 2018-2027 (USD BILLION)
  • TABLE 97 SOUTH AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 98 SOUTH AFRICA SELF-INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 99 SOUTH AFRICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 100 SOUTH AFRICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 101 SOUTH AFRICA OCULAR DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 102 SOUTH AFRICA OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 103 SOUTH AFRICA LIQUID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 104 SOUTH AFRICA SEMI-SOLID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 105 SOUTH AFRICA NASAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 106 SOUTH AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 107 SOUTH AFRICA TRANSDERMAL DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 108 SOUTH AFRICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 109 SOUTH AFRICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 110 SOUTH AFRICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 111 SOUTH AFRICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 112 SOUTH AFRICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 113 SOUTH AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 114 SOUTH AFRICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 115 SOUTH AFRICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 116 SOUTH AFRICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 117 SOUTH AFRICA NEBULIZERS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 118 SOUTH AFRICA DRUG DELIVERY MARKET, BY END USER, 2018-2027 (USD BILLION)
  • TABLE 119 SOUTH AFRICA DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
  • TABLE 120 REST OF MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)

LIST OF FIGURES

  • FIGURE 1 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: SEGMENTATION
  • FIGURE 2 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: DATA TRIANGULATION
  • FIGURE 3 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: DROC ANALYSIS
  • FIGURE 4 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET : COMPANY RESEARCH ANALYSIS
  • FIGURE 6 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: VENDOR SHARE ANALYSIS
  • FIGURE 9 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: SEGMENTATION
  • FIGURE 10 RISING PREVALENCE OF CHRONIC DISEASES AND NON CHRONIC DISEASES AND GROWTH IN THE DEVELOPMENT OF BIOLOGICS ARE EXPECTED TO BE KEY DRIVING FACTORS IN THE MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
  • FIGURE 11 ORAL DRUG DELIVERY IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET IN 2020 & 2027
  • FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET
  • FIGURE 13 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2019
  • FIGURE 14 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2019-2027 (USD BILLION)
  • FIGURE 15 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY PRODUCT TYPE, CAGR (2020-2027)
  • FIGURE 16 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY PRODUCT TYPE, LIFELINE CURVE
  • FIGURE 17 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY END USER, 2019
  • FIGURE 18 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY END USER, 2019-2027 (USD BILLION)
  • FIGURE 19 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY END USER, CAGR (2020-2027)
  • FIGURE 20 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 21 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, 2019
  • FIGURE 22 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
  • FIGURE 23 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
  • FIGURE 24 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
  • FIGURE 25 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: SNAPSHOT (2019)
  • FIGURE 26 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY COUNTRY (2019)
  • FIGURE 27 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY COUNTRY (2020 & 2027)
  • FIGURE 28 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY COUNTRY (2019 & 2027)
  • FIGURE 29 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY PRODUCT TYPE (2020-2027)
  • FIGURE 30 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: COMPANY SHARE 2019 (%)
Back to Top